Search Results - "Yin, John A. L."

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial by BURNETT, Alan K, HILLS, Robert K, MILLIGAN, Donald, KJELDSEN, Lars, KELL, Jonathan, RUSSELL, Nigel H, YIN, John A. L, HUNTER, Ann, GOLDSTONE, Anthony H, WHEATLEY, Keith

“…Antibody-directed chemotherapy for acute myeloid leukemia (AML) may permit more treatment to be administered without escalating toxicity. Gemtuzumab ozogamicin…”
Get full text

Guidelines for the diagnosis and management of aplastic anaemia by Marsh, Judith C. W., Ball, Sarah E., Cavenagh, Jamie, Darbyshire, Phil, Dokal, Inderjeet, Gordon‐Smith, Edward C., Keidan, Jane, Laurie, Andrew, Martin, Anna, Mercieca, Jane, Killick, Sally B., Stewart, Rhona, Yin, John A. L.

Get full text

Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy by Owen, Carolyn J., Toze, Cynthia L., Koochin, Anna, Forrest, Donna L., Smith, Clayton A., Stevens, Jane M., Jackson, Shannon C., Poon, Man-Chiu, Sinclair, Gary D., Leber, Brian, Johnson, Peter R.E., Macheta, Anthony, Yin, John A.L., Barnett, Michael J., Lister, T. Andrew, Fitzgibbon, Jude

“…Familial platelet disorder with propensity to myeloid malignancy (FPD/AML) is an autosomal dominant syndrome characterized by platelet abnormalities and a…”
Get full text

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia by Kell, William J., Burnett, Alan K., Chopra, Raj, Yin, John A.L., Clark, Richard E., Rohatiner, Ama, Culligan, Dominic, Hunter, Ann, Prentice, Archie G., Milligan, Donald W.

“…The feasibility of combining gemtuzumab ozogamicin (GO) with intensive chemotherapy as first-line treatment of acute myeloid leukemia (AML) was assessed in 72…”
Get full text

Outcome of Reduced Intensity Allografts in Patients Aged Over 45 Years with Acute Myeloid Leukaemia: Initial Results of the MRC AML15 Trial by Russell, Nigel H., Howman, Andrew J, Wheatley, Keith, Hills, Robert K, Craddock, Charles, Kjeldsen, Lars, Yin, John AL, Burnett, Alan K.

“…Abstract 523 The advent of reduced intensity conditioning (RIC) regimens permits the delivery of allogeneic stem cell transplant (alloSCT) with a potentially…”
Get full text

Attempts to Optimise Induction and Consolidation Chemotherapy in Patients with Acute Myeloid Leukaemia: Results of the MRC AML15 Trial by Burnett, Alan K, Hills, Robert K, Milligan, Donald, Hunter, Ann E., Goldstone, Anthony H., Prentice, Archie, Gibson, Brenda ES, Kjeldsen, Lars, Yin, John AL, Wheatley, Keith, Russell, Nigel H.

“…Abstract 484 On behalf of the NCRI AML Working Group, United Kingdom There is a general acceptance that survival in younger patients (<60 years) with AML has…”
Get full text

Low Dose Ara-C Versus Low Dose Ara-C and Arsenic Trioxide: the UK NCRI AML16 “Pick a Winner” Comparison by Russell, Nigel H., Hills, Robert K, Hunter, Ann E., Milligan, Donald, Kell, William J., Wheatley, Keith, McMullin, Mary Frances, Yin, John AL, Bowen, David T., Burnett, A.

“…Abstract 486 A significant proportion of older patients with AML are not treated with conventional intensive chemotherapy [1] because they are unfit or not…”
Get full text

Five New Pedigrees with Inherited RUNX1 Mutations Causing Familial Platelet Disorder with Propensity to Myeloid Malignancy (FPD/AML) by Owen, Carolyn J, Toze, Cynthia L, Koochin, Anna, Forrest, Donna L., Smith, Clayton A., Jackson, Shannon C, Poon, Man-Chiu, Sinclair, Gary D., Leber, Brian, Johnson, Peter, Macheta, Anthony, Yin, John AL, Barnett, Michael J., Lister, T. Andrew, Fitzgibbon, Jude

“…Familial platelet disorder with propensity to myeloid malignancy (FPD/AML) is an autosomal dominant syndrome characterised by platelet abnormalities and a…”
Get full text